Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD)

– Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history

– Significant decreases in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers associated with skeletal muscle damage

– EDG-5506 was well-tolerated at all doses

– Company continuing to enroll patients with BMD in the CANYON Phase 2 trial which now includes a pivotal cohort called GRAND CANYON

READ THE FULL PRESS RELEASE HERE